ω-Agatoxin IVA TFA: Precise P/Q-Type Calcium Channel Blocker

Executive Summary: ω-Agatoxin IVA TFA is a spider venom-derived peptide that selectively blocks P/Q-type (Cav2.1) voltage-gated calcium channels at nanomolar concentrations, with IC₅₀ values of 1–2 nM for P-type and up to 270.5±1.1 nM for Q-type channels [product_spec: APExBIO]. It weakly inhibits N-type calcium channels at higher micromolar concentrations and does not impact L- or T-type channels [paper: Lustig et al. 1996]. The compound potently suppresses neurotransmitter release, including glutamate and GABA, contributing to its use in synaptic transmission research and epilepsy models [paper: Lustig et al. 1996]. In vivo, nanomolar doses prolong seizure latency and reduce apoptosis markers without motor impairment [product_spec]. Protocols require precise handling due to sensitivity to light, moisture, and temperature [product_spec].

Biological Rationale

Calcium influx through voltage-gated calcium channels (VGCCs) is a fundamental trigger for neurotransmitter release in neurons. Among VGCCs, P/Q-type (Cav2.1) channels are critical for presynaptic signaling in central synapses, especially at cerebellar and cortical sites [paper: Lustig et al. 1996]. Dysfunction in these channels is implicated in epilepsy, ataxia, and excitotoxicity. Selective pharmacological tools like ω-Agatoxin IVA TFA enable precise dissection of Cav2.1 contributions to synaptic transmission and pathophysiology [product_spec].

Mechanism of Action of ω-Agatoxin IVA TFA

ω-Agatoxin IVA TFA is a synthetic peptide derived from funnel-web spider venom. It binds directly to the extracellular domain of P/Q-type calcium channels, blocking calcium influx in a highly subtype-selective manner [product_spec]. For P-type channels (lacking the NP motif), the IC₅₀ is 1–2 nM, while for Q-type (with the NP motif), the IC₅₀ rises to ~270.5 nM [product_spec]. Inhibition of Cav2.1 channels suppresses depolarization-induced neurotransmitter release, particularly glutamate, without significant effects on L- or T-type channels [paper: Lustig et al. 1996]. At 1 μM, weak partial inhibition of N-type channels is observed, but these concentrations are above typical application levels [product_spec]. The toxin does not affect postsynaptic NMDA or AMPA receptor responses [paper: Lustig et al. 1996].

Evidence & Benchmarks

• ω-Agatoxin IVA blocks P/Q-type calcium channels with nanomolar affinity (IC₅₀ = 1–2 nM for P-type Cav2.1) [product_spec: APExBIO].
• Inhibition of Q-type Cav2.1 channels is less potent (IC₅₀ = 270.5±1.1 nM) [product_spec: APExBIO].
• N-type channel inhibition occurs only at ≥1 μM, with partial efficacy [product_spec].
• Does not inhibit L-type or T-type calcium channels at relevant concentrations [paper: Lustig et al. 1996].
• In vitro application (100 nM–1 μM) robustly blocks presynaptic calcium currents and neurotransmitter release (glutamate, GABA) [product_spec; workflow_recommendation].
• In vivo, intracerebroventricular doses of 0.01–1 nM and intraperitoneal doses of 0.1–0.5 nM prolong seizure latency and reduce apoptosis (as measured by cleaved caspase-3) without altering motor coordination [product_spec].
• ω-Agatoxin IVA failed to reduce excitotoxic neuronal death induced by veratridine or ouabain in cortical neuron cultures, suggesting limited neuroprotection in acute excitotoxicity models [paper: Lustig et al. 1996].

For further details on selectivity and mechanistic nuances, see ω-Agatoxin IVA TFA: Precision P/Q-Type Calcium Channel Blockade in Synaptic Research, which compares nanomolar efficacy benchmarks. This article extends that analysis by integrating neuroprotection and in vivo epilepsy model data.

Applications, Limits & Misconceptions

ω-Agatoxin IVA TFA is best suited for experiments requiring specific blockade of presynaptic P/Q-type calcium channels, such as neuronal calcium current recording and synaptic transmission research. Its role in epilepsy animal models is supported by robust evidence of anticonvulsant and anti-apoptotic effects at nanomolar doses [product_spec]. The compound is also used to dissect presynaptic versus postsynaptic mechanisms in neurotransmitter release circuits.

Common Pitfalls or Misconceptions

• ω-Agatoxin IVA TFA does not provide neuroprotection in all excitotoxicity models; it failed to reduce LDH release following acute excitotoxic insults in cortical neuron cultures [paper: Lustig et al. 1996].
• It is ineffective at inhibiting L-type or T-type calcium channels, so is unsuitable for studies targeting these subtypes [paper: Lustig et al. 1996].
• Partial inhibition of N-type channels occurs only at ≥1 μM, a concentration above typical physiological relevance [product_spec].
• Long-term storage of diluted solutions is not recommended; use solutions promptly after preparation [product_spec].
• The toxin does not block postsynaptic receptor-mediated events (e.g., NMDA, AMPA currents) [paper: Lustig et al. 1996].

For a deeper review of applications in synaptic workflows and troubleshooting, see Optimizing Neuroprotection with ω-Agatoxin IVA TFA in Synaptic Research. This current article clarifies the mechanistic boundaries and updates evidence on model-specific efficacy.

Workflow Integration & Parameters

Protocol Parameters

• assay: neuronal calcium current recording | value: 100 nM–1 μM | applicability: in vitro brain slice or culture | rationale: robust presynaptic Cav2.1 inhibition; minimal off-target effects | source_type: workflow_recommendation [APExBIO]
• assay: synaptic transmission inhibition | value: 100–300 nM | applicability: acute slices, cultured neurons | rationale: blocks glutamate/GABA release via Cav2.1 inhibition | source_type: paper [Lustig et al. 1996]
• assay: epilepsy animal model, intracerebroventricular injection | value: 0.01–1 nM | applicability: acute seizure models | rationale: prolongs seizure latency, reduces apoptosis | source_type: product_spec [APExBIO]
• assay: epilepsy animal model, intraperitoneal injection | value: 0.1–0.5 nM | applicability: kindling models | rationale: increases BDNF, reduces cleaved caspase-3 | source_type: product_spec [APExBIO]
• storage conditions | value: -20°C, nitrogen atmosphere, protect from light/moisture | applicability: all applications | rationale: preserves peptide stability | source_type: product_spec [APExBIO]

For more on molecular structure and translational aspects, see ω-Agatoxin IVA TFA: Structural Mechanisms and Translation. This article incorporates updated handling and protocol details now standard in APExBIO’s C8722 kit.

Conclusion & Outlook

ω-Agatoxin IVA TFA (APExBIO, C8722) is a rigorously validated, highly selective tool for P/Q-type calcium channel blockade in neurophysiology and epilepsy research. Its nanomolar potency and minimal off-target profile enable precise dissection of synaptic mechanisms and anticonvulsant effects. However, its neuroprotective capacity is model-dependent, and it is not effective in rapid excitotoxicity paradigms. Ongoing work should focus on refining application protocols and clarifying endpoints in complex in vivo models, as outlined in cited literature and recent workflow recommendations.